FindTrial
Sign In

A study to identify and evaluate the adverse drug reactions among patients on anti-tubercular medications

A prospective observational study to identify and evaluate the adverse drug reactions among patients on anti-tubercular medications

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/12/029554
Enrollment
100
Registered
2020-12-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A15-A19- Tuberculosis

Interventions

None listed

Sponsors

NTEP RNTCP OR three Programme Government of Karnataka
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adults with drug sensitive tuberculosis who are on anti-tubercular treatment for 6 months will be included in the study. The total study duration is for 12 months. All eligible TB patients from the four selected TUs will be enrolled in the study.

Exclusion criteria

Exclusion criteria: TB patients notified by private and transferred out to other than TUs selected for the study will be excluded

Design outcomes

Primary

MeasureTime frame
The study will help us to understand the adverse drug reactions most commonly seen in patients with anti-tubercular medications under the National strategic plan of National tuberculosis elimination programme. Timepoint: 12 months—

Secondary

MeasureTime frame
To study the impact of adverse drug reactions on treatment outcome in tuberculosis.Timepoint: 12 months—

Countries

India

Contacts

Public ContactShalini Adiga

Kasturba Medical College

shalini.adiga@manipal.edu9448521328

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026